Javier De Castro-Carpeño

24PUBLICATIONS
207CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jul 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|Apr 13, 2026
Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Federico Rojo, Enriqueta Felip, Oscar Juan Vidal

|Mar 10, 2026
Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Belén Sierra-Rodero, Ángeles Gil-González, Marta Molina-Alejandre

|Mar 06, 2026
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.

Zofia Piotrowska, Myung-Ju Ahn, Pei Jye Voon

|Mar 04, 2026
Unveiling miR-451a and miR-142-3p as prognostic markers in non-small cell lung cancer via small extracellular vesicle liquid biopsy.

Miranda Burdiel, Ana Arauzo-Cabrera, Julia Jiménez

|Jan 15, 2026
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.

Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal

Pageof 4

Frequent Collaborators

8 joint publications

Ernest Nadal

8 joint publications

Mariano Provencio Pulla

6 joint publications

Alberto Cruz-Bermúdez

6 joint publications

Amelia Insa Molla